St. Francis plans $23 million Carmel hospital
Franciscan St. Francis Health plans to open a short-stay medical center in Carmel, creating 76 jobs by 2015, the health system announced Monday morning.
Health Care & Insurance
Articles
Lilly names new head of cancer drug business
Eli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.
Lilly takeover provision to be voted on again
The effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board is on the agenda of the company’s April 18 annual meeting.
Diabetes boom sparks Roche expansion
Roche Diagnostics Corp. is expanding one of its Indianapolis manufacturing plants to keep up with growing sales of its leading brand of blood glucose monitors.
Medicaid expansion could tax community health centers
The president of the Indiana Primary Health Care Association wants to double the number of federally qualified community health centers in Indiana in the next five years.
Repeated price cuts take glow off Endocyte IPO
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
Health insurers expect hit from reform rule
Major health insurers, including WellPoint, say a provision that requires them to spend a certain percentage of the premiums they collect on care-related costs will eat into earnings this year.
Arcadia reports smaller loss on increased revenue
The Indianapolis-based health care company lost $2.3 million on revenue of $26.2 million in its third fiscal quarter.
Daniels leads guvs’ health-care revolt
Boy does Gov. Mitch Daniels have an ultimatum for President Obama: Wave off the health reform law or else I’ll do nothing to help while it wreaks havoc on Hoosier citizens.
Recent successes don’t change Lilly’s outlook
Eli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past 18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have paltry sales prospects.
Lilly collaboration with outside researchers yields first deal
Eli Lilly and Co.’s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz said it’s just the first of many such collaborations.
Eli Lilly CEO Lechleiter sees 2010 pay fall 22 percent
Eli Lilly and Co. Chairman and CEO John Lechleiter received compensation valued at $12.7 million last year, down 22 percent from 2009 largely due to a change in how the drugmaker handles equity awards.
2010 compensation fell about 20 percent for top Lilly execs
Compensation for Eli Lilly and Co.’s top executives fell last year due to a change to its stock award program and as the company struggled to bring new medicines to market.
Endocyte again changes terms of public offering
The West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more than previously announced, but at a lower price of $6 each.
Indiana Farm Bureau unveiling ads during Super Bowl
The insurer’s new campaign, developed by local advertising firm Young & Laramore, focuses on real-life situations amid a crowded field of competitors.
Panel OKs criminal checks on medical workers
Physicians, dentists, nurses, veterinarians, pharmacists and other medical workers would have to pay for a national criminal background check when applying for a state license under a bill pending with the Indiana Senate.
Health insurance brokers set for shakeout
Health insurance brokers, who match up employers with health insurance policies, are about to have a brighter light shone on the commissions they earn from insurers. The likely result: Commissions will fall or flatline and, eventually, fall away in favor of fee-based business models.
Struggling Lilly turns to antidepressant Cymbalta for lift
Cymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition arrives in 2013.
Baldwin & Lyons reports higher revenue, lower profit
Indianapolis-based insurer of car and truck fleets posts quarterly profit slightly lower than a year ago. Revenue, however, rose to $67.7 million, up from $60.8 million in 2009.
Lilly, Bristol-Myers halt enrollment in lung-cancer trial
Eli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung cancer drug over concerns about patients developing blood clots.